Changes of adrenomedullin and natriuretic peptides in patients with adrenal medullary hyperplasia prior to and following pharmacological therapy and adrenalectomy

Zhou,Pang‑Hu; Shi,Lei; Hu,Wei; Zhang,Xiao‑Bin; Wang,Wei; Zhang,Li‑Jun

doi:10.3892/etm.2016.3418

Changes of adrenomedullin and natriuretic peptides in patients with adrenal medullary hyperplasia prior to and following pharmacological therapy and adrenalectomy

Authors:
- Pang‑Hu Zhou
- Lei Shi
- Wei Hu
- Xiao‑Bin Zhang
- Wei Wang
- Li‑Jun Zhang
View Affiliations

Affiliations: Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: June 3, 2016 https://doi.org/10.3892/etm.2016.3418
Pages: 864-872

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the pathophysiological functions of adrenomedullin (ADM), atrial and brain natriuretic peptides (ANP and BNP) in patients with adrenal medullary hyperplasia (AMH). Plasma ADM, ANP and BNP concentrations were measured in 20 patients with AMH, 35 patients with essential hypertension (EH), and 40 healthy control subjects. Following effective antihypertensive therapy, the values in AMH and EH patients were measured again and laparoscopic adrenalectomy was performed for AMH patients. At 2 weeks after surgery, the three peptides were measured again. The AMH patients had higher plasma concentrations of ADM, ANP and BNP compared with the EH and control subjects. There were significant differences in the values of ADM, ANP and BNP between adrenal vein and inferior vena cava and between AMH and contralateral adrenal vein. Plasma ADM concentration was correlated with serum epinephrine and norepinephrine and urine vanillylmandelic acid, in addition to systolic and diastolic blood pressure, left ventricular ejection fraction, left ventricular mass index and ANP and BNP values in the AMH group. Following antihypertensive treatment, ADM, ANP and BNP were significantly decreased in EH patients, but remained unchanged in AMH subjects. However, these concentrations significantly decreased following surgery. Therefore, the present results suggest that ADM, ANP and BNP may be involved in regulating adrenal medulla functions.

View Figures

View References

1	Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H and Eto T: Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma. 1993. Biochem Biophys Res Commun. 425:548–555. 2012. View Article : Google Scholar : PubMed/NCBI
2	Cheung BM, Li CY and Wong LY: Adrenomedullin: Its role in the cardiovascular system. Semin Vasc Med. 4:129–134. 2004. View Article : Google Scholar : PubMed/NCBI
3	Minamino N: Adrenomedullin, its distribution and regulation of production. Nihon Rinsho. 62(Suppl 9): S193–S197. 2004.
4	Cheung BM and Tang F: Adrenomedullin: Exciting new horizons. Recent Pat Endocr Metab Immune Drug Discov. 6:4–17. 2012. View Article : Google Scholar : PubMed/NCBI
5	Wong HK, Cheung TT and Cheung BM: Adrenomedullin and cardiovascular diseases. JRSM Cardiovasc Dis. 1:pii: cvd.2012.012003. 2012.PubMed/NCBI
6	Li Y, Jiang C, Wang X, Zhang Y, Shibahara S and Takahashi K: Adrenomedullin is a novel adipokine: Adrenomedullin in adipocytes and adipose tissues. Peptides. 28:1129–1143. 2007. View Article : Google Scholar : PubMed/NCBI
7	Nishikimi T, Kuwahara K, Nakagawa Y, Kangawa K and Nakao K: Adrenomedullin in cardiovascular disease: A useful biomarker, its pathological roles and therapeutic application. Curr Protein Pept Sci. 14:256–267. 2013. View Article : Google Scholar : PubMed/NCBI
8	Arjamaa O: Physiology of natriuretic peptides: The volume overload hypothesis revisited. World J Cardiol. 6:4–7. 2014. View Article : Google Scholar : PubMed/NCBI
9	Chowdhury P, Kehl D, Choudhary R and Maisel A: The use of biomarkers in the patient with heart failure. Curr Cardiol Rep. 15:3722013. View Article : Google Scholar : PubMed/NCBI
10	Clerico A, Giannoni A, Vittorini S and Passino C: Thirty years of the heart as an endocrine organ: Physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol. 301:H12–H20. 2011. View Article : Google Scholar : PubMed/NCBI
11	Federico C: Natriuretic peptide system and cardiovascular disease. Heart Views. 11:10–15. 2010.PubMed/NCBI
12	Kuhn M: Endothelial actions of atrial and b-type natriuretic peptides. Br J Pharmacol. 166:522–531. 2012. View Article : Google Scholar : PubMed/NCBI
13	Lu WW and Qi YF: Cardiovascular effects and pathophysiological significance of adrenomedullin family peptides. Sheng Li Ke Xue Jin Zhan. 44:177–182. 2013.(In Chinese). PubMed/NCBI
14	Whitworth JA: World Health Organization, International Society of Hypertension Writing Group: 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 21:1983–1992. 2003. View Article : Google Scholar : PubMed/NCBI
15	Cotesta D, Caliumi C, Alò P, Petramala L, Reale MG, Masciangelo R, Signore A, Cianci R, D'Erasmo E and Letizia C: High plasma levels of human chromogranin a and adrenomedullin in patients with pheochromocytoma. Tumori. 91:53–58. 2005.PubMed/NCBI
16	Ohta H, Tsuji T, Asai S, Tanizaki S, Sasakura K, Teraoka H, Kitamura K and Kangawa K: A simple immunoradiometric assay for measuring the entire molecules of adrenomedullin in human plasma. Clin Chim Acta. 287:131–143. 1999. View Article : Google Scholar : PubMed/NCBI
17	Ohta H, Tsuji T, Asai S, Sasakura K, Teraoka H, Kitamura K and Kangawa K: One-step direct assay for mature-type adrenomedullin with monoclonal antibodies. Clin Chem. 45:244–251. 1999.PubMed/NCBI
18	Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M and Nakao K: Localization and mechanism of secretion of b-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 90:195–203. 1994. View Article : Google Scholar : PubMed/NCBI
19	Beltowski J and Jamroz A: Adrenomedullin-what do we know 10 years since its discovery? Pol J Pharmacol. 56:5–27. 2004.PubMed/NCBI
20	Kato J, Kitamura K and Eto T: Plasma adrenomedullin level and development of hypertension. J Hum Hypertens. 20:566–570. 2006. View Article : Google Scholar : PubMed/NCBI
21	Garcia MA, Martín-Santamaría S, de Pascual-Teresa B, Ramos A, Julián M and Martínez A: Adrenomedullin: A new and promising target for drug discovery. Expert Opin Ther Targets. 10:303–317. 2006. View Article : Google Scholar : PubMed/NCBI
22	Marín MR, Arenas MF, Valverde FM, Garaulet ET, Maderuelo MM, Avilés AM, Quirante FP and Blázquez AA: Laparoscopic adrenalectomy for nonfamilial adrenal medullary hyperplasia. JSLS. 17:433–439. 2013. View Article : Google Scholar : PubMed/NCBI
23	Thouennon E, Pierre A, Yon L and Anouar Y: Expression of trophic peptides and their receptors in chromaffin cells and pheochromocytoma. Cell Mol Neurobiol. 30:1383–1389. 2010. View Article : Google Scholar : PubMed/NCBI
24	Sergeeva IA and Christoffels VM: Regulation of expression of atrial and brain natriuretic peptide, biomarkers for heart development and disease. Biochim Biophys Acta. 1832:2403–2413. 2013. View Article : Google Scholar : PubMed/NCBI
25	Saito Y: Roles of atrial natriuretic peptide and its therapeutic use. J Cardiol. 56:262–270. 2010. View Article : Google Scholar : PubMed/NCBI
26	Nishikimi T: Adrenomedullin in essential hypertension. Nihon Rinsho. 62(Suppl 9): S260–S263. 2004.(In Japanese).
27	Soualmia H, Ayadi I, Omar S, Feki M, Drissa H, Mebazaa A and Kaabachi N: Atrial natriuretic peptide and brain natriuretic peptide release in human essential hypertension. Clin Lab. 55:120–127. 2009.PubMed/NCBI
28	Lee YJ, Lin SR, Shin SJ, Lai YH, Lin YT and Tsai JH: Brain natriuretic peptide is synthesized in the human adrenal medulla and its messenger ribonucleic acid expression along with that of atrial natriuretic peptide are enhanced in patients with primary aldosteronism. J Clin Endocrinol Metab. 79:1476–1482. 1994. View Article : Google Scholar : PubMed/NCBI
29	Letizia C, De Toma G, Cerci S, Massa R, Coassin S, Subioli S, Scuro L and De Ciocchis A: Adrenomedullin levels are high in primary aldosteronism due to adenoma and decline after surgical cure. Blood Press. 7:19–23. 1998. View Article : Google Scholar : PubMed/NCBI
30	Kato J, Etoh T, Kitamura K and Eto T: Atrial and brain natriuretic peptides as markers of cardiac load and volume retention in primary aldosteronism. Am J Hypertens. 18:354–357. 2005. View Article : Google Scholar : PubMed/NCBI
31	Letizia C, De Toma G, Caliumi C, Cerci S, Massa R, Loria RD, Alo P, Marinoni EM, Diacinti D and D'Erasmo E: Plasma adrenomedullin concentrations in patients with adrenal pheochromocytoma. Horm Metab Res. 33:290–294. 2001. View Article : Google Scholar : PubMed/NCBI